FDA approves technivie for hepatitis C

FDA approves technivie for hepatitis C
Technivie (ombitasvir, paritaprevir and ritonavir) has been approved by the U.S. Food and Drug Administration, in tandem with ribavirin, to treat hepatitis C genotype 4 infection among people without cirrhosis and without scarring.

(HealthDay)—Technivie (ombitasvir, paritaprevir and ritonavir) has been approved by the U.S. Food and Drug Administration, in tandem with ribavirin, to treat hepatitis C genotype 4 infection among people without cirrhosis and without scarring.

Technivie is the first drug to be sanctioned to treat genotype 4 hepatitis C infection without requiring co-use of the drug interferon, the agency said Friday in a news release.

The Technivie/ combination was evaluated in a clinical study involving 135 people. Of the participants who received Technivie with ribavirin, 100 percent achieved a sustained virologic response, while 91 percent of those who received Technivie without ribavirin achieved a sustained . The most commonly reported side effects included fatigue, asthenia, nausea, insomnia, pruritus, and other skin reactions.

Technivie's label includes a warning of the possibility of elevated liver enzymes, a result that occurred most often among women who took contraceptives containing ethinyl estradiol. Such contraceptives should be discontinued before these women take Technivie, the FDA advised.

Technivie is marketed by AbbVie, based in North Chicago.


Explore further

Interferon-free therapies for hep C virus look promising

More information: More Information

Health News Copyright © 2015 HealthDay. All rights reserved.

Citation: FDA approves technivie for hepatitis C (2015, July 25) retrieved 20 November 2019 from https://medicalxpress.com/news/2015-07-fda-technivie-hepatitis.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
21 shares

Feedback to editors

User comments